Engineered immune cells take on advanced kidney cancer in new trial
NCT ID NCT06245915
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial tests a new treatment called AB-2100 for people with advanced or metastatic clear-cell renal cell carcinoma that has come back after standard treatments. AB-2100 is made from the patient's own immune cells, which are modified in the lab to better recognize and attack cancer cells. The study aims to see if this therapy is safe and whether it can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AB-2100 (a type of modified immune cell therapy called Integrated Circuit T cells)
What this could lead to
If successful, this could lead to a new treatment option for people with advanced kidney cancer that has stopped responding to standard therapies.
What could go wrong
This is an early-phase trial with only 37 participants, so results may not apply to everyone. The therapy may cause serious side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope
Duarte, California, 91010, United States
-
Dana Farber Cancer Institue
Boston, Massachusetts, 02215, United States
-
Huntsman Cancer Institute - Univ of Utah Health
Salt Lake City, Utah, 84112, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Mayo Clinic Hospital
Phoenix, Arizona, 85054, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Perlmutter Cancer Center - NYU Langone Health
New York, New York, 10016, United States
-
University of Iowa and Holden Comprehensive Cancer Center
Iowa City, Iowa, 52242, United States